Trademark: 86245232
Word
MAGNAFOLATE-C
Status Date
Monday, October 30, 2023
Registration Number
5266274
Registration Date
Tuesday, August 15, 2017
Filing Date
Monday, April 7, 2014
Published for Opposition
Tuesday, March 28, 2017
5 Medicines for human purposes, namely, L-5- methyl tetrahydrofolate for use as a contraceptive; pharmaceutical preparations for the treatment and prevention of diseases and disorders of the respiratory system, gastrointestinal system, endocrine system, cardiovascular system, nervous system, masculoskeletal system, urinary system, integumentary system and reproductive system; pharmaceutical preparations for treatment of blood disease and disorder; dermatologic pharmaceutical preparations; hormone therapy preparations; pharmaceutical preparations for the treatments of colds, coughs and influenza; pharmaceutical preparations for ophthalmic use; pharmaceutical preparations for treating dandruff, laxatives, analgesics, contraceptives, antiseptics; pharmaceutical preparations for treatment of hypertension; pharmaceutical preparations for treatment of obesity; anti allergic pharmaceutical preparations; pharmaceutical preparations for treatment of gout; anti-inflammatory pharmaceuticals; contraceptive preparations; dietetic foods, namely, folic acid for the treatment of vitamin deficiency; dietetic substances adapted for medical use, namely, folic acid for the treatment of vitamin deficiency; food for babies; nutritional supplements; dietary supplement for animals; antibiotics; vitamin preparations; drugs for medical purposes for the treatment of subacute encephali associated with dementia and vacuolar myelopathy, physiological and pathological vascular and cardiovascular disorders such as premature occlusive arterial diseases, severe vascular diseases in infancy and childhood, progressive arterial stenosis, intermittent claudication, renal vascular hypertension, ischemic cerebrovascular diseases, premature occlusive retinal artery and retinal vein, crebral occlusive arterial diseases, occlusive peripheral arterial diseases, and premature death caused by thromboembolic diseases and/or ischemic heart diseases, autoimmune diseases such as psoriasis, celiac disease, arthritis and inflammatory conditions, megaloblastic anemia caused by folate inficiency, intestinal malabsorption, used as antidote for folic acid antagonists, used for preventing serious toxic effects caused by methotrexate overdose or high-dose therapy, reducing risks of woman miscarriage and/or production of fetuses with neural tube defects, cleft lip and/or palate defects, keeping and/or normalizing homocysteine levels and/or metabolism, changes synthesis of and/or functions and/or variations in dna and rna and changes in synthesis of cells and depression
1 Industrial chemicals; chemical preparations for scientific purposes, other than for medical or veterinary use; calcium salts; chemical preparations and raw materials in the nature of L-5- methyl tetrahydrofolate for use in the manufacture pharmaceutical, medical and nutritional products; chemicals for use in industry and science; chemicals for use in the pharmaceutical, nutritional and dietary industries
The mark consists of the stylized wording "MAGNAFOLATE-C".
Color is not claimed as a feature of the mark.
Oct 30, 2023
Notice Of Acceptance Of Sec. 8 - E-Mailed
Oct 30, 2023
Registered - Sec. 8 (6-Yr) Accepted
Oct 30, 2023
Case Assigned To Post Registration Paralegal
Jun 27, 2023
Teas Section 8 Received
Aug 15, 2022
Courtesy Reminder - Sec. 8 (6-Yr) E-Mailed
Aug 15, 2017
Registered-Principal Register
Jul 14, 2017
Notice Of Acceptance Of Statement Of Use E-Mailed
Jul 13, 2017
Allowed Principal Register - Sou Accepted
Jul 6, 2017
Statement Of Use Processing Complete
Jun 9, 2017
Use Amendment Filed
Jul 5, 2017
Case Assigned To Intent To Use Paralegal
Jun 9, 2017
Teas Statement Of Use Received
May 23, 2017
Noa E-Mailed - Sou Required From Applicant
Mar 28, 2017
Official Gazette Publication Confirmation E-Mailed
Mar 28, 2017
Published For Opposition
Mar 8, 2017
Notification Of Notice Of Publication E-Mailed
Feb 22, 2017
Law Office Publication Review Completed
Feb 8, 2017
Approved For Pub - Principal Register
Jan 18, 2017
Teas Change Of Correspondence Received
Sep 29, 2016
Teas/Email Correspondence Entered
Sep 29, 2016
Correspondence Received In Law Office
Sep 29, 2016
Teas Response To Office Action Received
May 19, 2016
Notification Of Non-Final Action E-Mailed
May 19, 2016
Non-Final Action E-Mailed
May 19, 2016
Non-Final Action Written
Feb 3, 2016
Teas/Email Correspondence Entered
Feb 3, 2016
Correspondence Received In Law Office
Jan 28, 2016
Teas Response To Office Action Received
Sep 3, 2015
Notification Of Non-Final Action E-Mailed
Sep 3, 2015
Non-Final Action E-Mailed
Sep 3, 2015
Non-Final Action Written
Aug 14, 2015
Previous Allowance Count Withdrawn
Aug 4, 2015
Withdrawn From Pub - Og Review Query
Jul 21, 2015
Law Office Publication Review Completed
Jul 15, 2015
Assigned To Lie
Jul 1, 2015
Approved For Pub - Principal Register
Jun 19, 2015
Teas/Email Correspondence Entered
Jun 19, 2015
Correspondence Received In Law Office
Jun 19, 2015
Teas Request For Reconsideration Received
Jan 5, 2015
Notification Of Final Refusal Emailed
Jan 5, 2015
Final Refusal E-Mailed
Jan 5, 2015
Final Refusal Written
Dec 10, 2014
Teas/Email Correspondence Entered
Dec 10, 2014
Correspondence Received In Law Office
Dec 10, 2014
Teas Response To Office Action Received
Jul 16, 2014
Notification Of Non-Final Action E-Mailed
Jul 16, 2014
Non-Final Action E-Mailed
Jul 16, 2014
Non-Final Action Written
Jul 14, 2014
Assigned To Examiner
Apr 21, 2014
New Application Office Supplied Data Entered
Apr 10, 2014
New Application Entered
Trademark Alertz updated from USPTO on 2030-01-24
